Keating Financial Advisory Services’s iShares Biotechnology ETF IBB Stock Holding History

Keating Financial Advisory Services’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73K	Hold	384	–	–	0.01%	585
2026 Q1	$64.8K	Hold	384	–	–	0.01%	561
2025 Q4	$64.8K	Buy	+384	New	+$62.4K	0.01%	600

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Keating Financial Advisory Services's IBB Position: Q2 2026 in Review

Keating Financial Advisory Services held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 384 shares worth $73K. The position accounts for 0.01% of the portfolio, ranked #585.

Keating Financial Advisory Services first reported a position in IBB in Q4 2025 and has held it in 3 quarters since. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Keating Financial Advisory Services held 384 shares of iShares Biotechnology ETF worth $73K as of Q2 2026.
Keating Financial Advisory Services left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #585 holding.
Keating Financial Advisory Services first reported a position in iShares Biotechnology ETF in Q4 2025 and has held it in 3 quarters since.
960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.